Millipore Sigma Vibrant Logo

493800 PARP Inhibitor VI, NU1025 - CAS 90417-38-2 - Calbiochem

The PARP Inhibitor VI, NU1025, also referenced under CAS 90417-38-2, controls the biological activity of PARP. This small molecule/inhibitor is primarily used for Cell Structure applications.

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: 8-Hydroxy-2-methylquinazoline-4-one

Primary Target: PARP
View Products on Sigmaaldrich.com
493800
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
90417-38-2C₉H₈N₂O₂

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
493800-5MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 5 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewA potent inhibitor poly(ADP-ribose) polymerase (PARP; IC50 = 0.40 µM). Has been shown to potentiate the cytotoxicity of the DNA-methylating agent MTIC [5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide] and ionizing irradiation in murine L210 leukemia cells.
      Catalogue Number493800
      Brand Family Calbiochem®
      Synonyms8-Hydroxy-2-methylquinazoline-4-one
      References
      ReferencesDelaney, C.A., et al. 2000. Clin. Cancer Res. 6, 2860.
      Boulton, S., et al. 1999. Carcinogenesis 20, 199.
      Bowman, K.J., et al. 1998. Br. J. Cancer 78, 1269.
      Griffin, R.J., et al. 1998. J. Med. Chem. 41, 5247.
      Griffin, R.J., et al. 1996. Pharm. Sci. 2, 43.
      Boulton, S., et al. 1995. Br. J. Cancer 72, 849.
      Griffin, R.J., et al. 1995. Anticancer Drug Res. 10, 507.
      Product Information
      CAS number90417-38-2
      ATP CompetitiveN
      FormOff-white solid
      Hill FormulaC₉H₈N₂O₂
      Chemical formulaC₉H₈N₂O₂
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetPARP
      Primary Target IC<sub>50</sub>0.4 µM against poly(ADP-ribose) polymerase (PARP)
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      493800-5MG 04055977272826

      Documentation

      PARP Inhibitor VI, NU1025 - CAS 90417-38-2 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      PARP Inhibitor VI, NU1025 - CAS 90417-38-2 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      493800

      Références bibliographiques

      Aperçu de la référence bibliographique
      Delaney, C.A., et al. 2000. Clin. Cancer Res. 6, 2860.
      Boulton, S., et al. 1999. Carcinogenesis 20, 199.
      Bowman, K.J., et al. 1998. Br. J. Cancer 78, 1269.
      Griffin, R.J., et al. 1998. J. Med. Chem. 41, 5247.
      Griffin, R.J., et al. 1996. Pharm. Sci. 2, 43.
      Boulton, S., et al. 1995. Br. J. Cancer 72, 849.
      Griffin, R.J., et al. 1995. Anticancer Drug Res. 10, 507.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision13-August-2008 RFH
      Synonyms8-Hydroxy-2-methylquinazoline-4-one
      DescriptionA potent poly(ADP-ribose) polymerase (PARP) inhibitor (IC50 = 400 nM) that potentiates the cytotoxicity of various DNA-active agents, including the DNA-methylating compound MTIC [5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide], the DNA strand break-inducing drug temozolomide, topotecan, bleomycin, and ionizing radiation in murine L1210 leukemia cells, Chinese hamster ovary cells, and in a variety of human tumor cell lines.
      FormOff-white solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number90417-38-2
      Chemical formulaC₉H₈N₂O₂
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (25 mg/ml). This solution can be further diluted 1:100 in tissue culture medium before use.
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Standard Handling
      ReferencesDelaney, C.A., et al. 2000. Clin. Cancer Res. 6, 2860.
      Boulton, S., et al. 1999. Carcinogenesis 20, 199.
      Bowman, K.J., et al. 1998. Br. J. Cancer 78, 1269.
      Griffin, R.J., et al. 1998. J. Med. Chem. 41, 5247.
      Griffin, R.J., et al. 1996. Pharm. Sci. 2, 43.
      Boulton, S., et al. 1995. Br. J. Cancer 72, 849.
      Griffin, R.J., et al. 1995. Anticancer Drug Res. 10, 507.